The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass
Abstract
Pathogenic mutations in the melanocortin-4 receptor (MC4R) are associated with obesity, increased linear growth, and higher bone mass in children, and rodent studies have indicated an effect of the MC4R on bone turnover. Furthermore, GLP-1 receptor agonists (GLP-1 RAs) may influence bone metabolism. However, these associations have not been assessed in adults with pathogenic MC4R mutations. Thus, we wished to assess the impact of the MC4R on bone mass and metabolism. Secondly, we wished to investigate the impact of the GLP-1 RA liraglutide on bone mass in adults with pathogenic MC4R mutations. 17 patients with obesity-causing MC4R mutations (BMI: 35.5 ± 7.6) and 35 matched control participants with common obesity (BMI: 34.3 ± 7.1) underwent a DEXA scan for assessment of bone mineral density (BMD), bone mineral apparent density [BMAD = (BMD/√(bone area)], and bone turnover markers (BTMs). Individuals with a BMI above 28 (14 MC4R mutation carriers and 28 matched control participants) underwent 16 weeks treatment with liraglutide 3.0 mg. The MC4R group had higher BMD [mean difference: 0.065 g/m 2 (- 0.008 to 0.138), p = 0.03], but BMAD and BTMS were not different compared to the control group. In response to liraglutide, BMAD increased in the control group, compared to no change in the MC4R group [mean group difference: 0.0007 (0.0001-0.001), p = 0.04]. In conclusion, BMD is increased in MC4R causal obesity compared to common obesity, but when corrected for body size (BMAD), bone mass was not increased, and no evidence of an influence of the MC4R on bone metabolism in adults was found. Liraglutide treatment did not change bone metabolism in MC4R causal obesity, but increased bone mass as measured by BMAD in common obesity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MC4R deficiency, which represents the most common genetic form of obesity, is characterized by hyperphagia (increased drive to eat), weight gain that begins in the first 5 years of life, disproportionate hyperinsulinemia and accelerated linear growth in childhood7,12,13.”
From Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency (2025) · cites this paper as [13]
Citations
Cites
Targeted disruption of the melanocortin-4 receptor results in obesity in mice
Huszar, D., Lynch, C. A., Fairchild-Huntress, V., Dunmore, J. H., Fang, Q., Berkemeier, L. R., Gu, W., Kesterson, R. A., Boston, B. A., Cone, R. D., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)81865-6 · Cited by 3,030
Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene
Farooqi, I. S., Keogh, J. M., Yeo, G. S. H., Lank, E. J., Cheetham, T., & O'Rahilly, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022050 · Cited by 1,778
Leptin Regulates Bone Formation via the Sympathetic Nervous System
Takeda, S., Elefteriou, F., Levasseur, R., Liu, X., Zhao, L., Parker, K. L., Armstrong, D., Ducy, P., & Karsenty, G. (2002) · Cell · doi:10.1016/s0092-8674(02)01049-8 · Cited by 1,735
for the IOF-IFCC Bone Marker Standards Working Group, Vasikaran, S., Eastell, R., Bruyère, O., Foldes, A. J., Garnero, P., Griesmacher, A., McClung, M., Morris, H. A., Silverman, S., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1501-1 · Cited by 1,212 · cited 1×
“intact P1NP, and osteocalcin were measured by a chemiluminescence method [20, 21].”
MethodMelanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity
Vaisse, C., Clement, K., Durand, E., Hercberg, S., Guy-Grand, B., & Froguel, P. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9238 · Cited by 897
Farooqi, I. S., Yeo, G. S. H., Keogh, J. M., Aminian, S., Jebb, S. A., Butler, G., Cheetham, T., & O’Rahilly, S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9397 · Cited by 815
The Molecular Genetics of Rodent Single Gene Obesities
Leibel, R. L., Chung, W. K., & Chua, S. C. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.51.31937 · Cited by 286
Hinney, A., Bettecken, T., Tarnow, P., Brumm, H., Reichwald, K., Lichtner, P., Scherag, A., Nguyen, T. T., Schlumberger, P., Rief, W., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2056 · Cited by 209
Iepsen, E. W., Lundgren, J. R., Hartmann, B., Pedersen, O., Hansen, T., Jørgensen, N. R., Jensen, J.-E. B., Holst, J. J., Madsbad, S., & Torekov, S. S. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1176 · Cited by 193
Self-citationLarsen, L. H., Echwald, S. M., Sørensen, T. I. A., Andersen, T., Wulff, B. S., & Pedersen, O. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0497 · Cited by 176
Research works printed but not linked: 1
- Glendenning P (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Clin Biochem Rev 32:45–47
Cited by
Melanocortin‐4 receptor complexity in energy homeostasis,obesity and drug development strategies
Fatima, M. T., Ahmed, I., Fakhro, K. A., & Akil, A. A. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14618 · Cited by 57
“Mo et al60 reported various MC4R ligands, including AgRP and Ipsen 5i inverse agonists, at the Gs-cAMP signalling pathway, to regulate ERK activation in wild-type and six naturally occurring con- stitutively active mutant (CAM) MC4R.”
BackgroundInfluentialLiu, T., Ji, R.-L., & Tao, Y.-X. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108044 · Cited by 34
Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic Review
Viggers, R., Rasmussen, N. H., & Vestergaard, P. (2023) · JBMR Plus · doi:10.1002/jbm4.10817 · Cited by 29
Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency
Bhatnagar, P., Ahmad, N. N., Li, X., Coghlan, M., Kaplan, L. M., & Farooqi, I. S. (2025) · Nature Medicine · doi:10.1038/s41591-025-03913-2 · Cited by 20
“MC4R deficiency, which represents the most common genetic form of obesity, is characterized by hyperphagia (increased drive to eat), weight gain that begins in the first 5 years of life, disproportionate hyperinsulinemia and accelerated linear growth in childhood 7,12,13 .”
MC4R in Central and Peripheral Systems
Wei, R., Li, D., Jia, S., Chen, Y., & Wang, J. (2023) · Advanced Biology · doi:10.1002/adbi.202300035 · Cited by 22
Medical semiology of patients with monogenic obesity: A systematic review
Renard, É., Thevenard-Berger, A., & Meyre, D. (2024) · Obesity Reviews · doi:10.1111/obr.13797 · Cited by 18
Xu, H., Zhang, H., Fang, Y., Yang, H., Chen, Y., Zhang, C., & Lin, G. (2021) · Cell Regeneration · doi:10.1186/s13619-021-00081-9 · Cited by 9
“The increased final height and bone mass in individuals with pathogenic MC4R mutations suggest that MC4R may have a role in bone turnover (Lepsen et al., 2020; Martinelli et al., 2011).”
BackgroundHassan, M., Shahzadi, S., Yasir, M., Chun, W., & Kloczkowski, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-45347-1 · Cited by 12
The Impact of Bariatric Surgery on Bone Health: State of the Art and New Recognized Links
Mendonça, F. M., Soares, R. A., Carvalho, D. M., & Freitas, P. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1767-5581 · Cited by 9
“Patients with mutations in MC4R gene had higher BMD than matched control participants, underlining a probable influence of genes in these relationship between obesity and bone metabolism (that can, in theory, be also a factor to consider after bariatric surgery) [151].”
BackgroundInvestigating the genetics of equine endocrine dysfunction
Cash, C. M. (2023) · Queensland University of Technology · doi:10.5204/thesis.eprints.238537
王, 钰. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.163787
Janjua, Q. M., Khanam, R., Saeed, S., Manzoor, J., Haseeb, A., Hanook, S., Bonnefond, A., Arslan, M., & Froguel, P. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02047-w
Neural Melanocortin Receptors in Fish: Insights into Growth Regulation and Aquaculture Advancement
Ji, R., & Tao, Y. (2026) · Biomolecules · doi:10.3390/biom16060839
The application of GLP-1 receptor agonists in obesity due to MC4R deficiency
Ding, M., Luo, Y., & Ji, L. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2026.58
Metadata
- Authors
- Iepsen, E. W., Zhang, J., Hollensted, M., Madsbad, S., Hansen, T., Holst, J. J., Jørgensen, N. R., Holm, J.-C., & Torekov, S. S.
- Affiliations
- University of Copenhagen (DK)
- Hvidovre Hospital (DK)
- University of Southern Denmark (DK)
- Corresponding author
- Iepsen, Eva W.
- Torekov, Signe S.
- ORCID
- Venue
- Journal of Bone and Mineral Metabolism
- Published
- 2019-08-30
- Volume
- 38
- Issue
- 1
- Pages
- 117-125
- ISSN
- 0914-8779 (ISSN-L)
- 1435-5604
- OpenAlex
- W2970521377
- Cited by
- 15
- References
- 29
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 3
- FWCI
- 1.33
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Bone and Mineral Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Funders
- Lundbeckfonden
- Novo Nordisk Fonden
- Aase og Ejnar Danielsens Fond
- Augustinus Fonden
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- MC4R mutations, melanocortin-4 receptor, obesity, bone mineral density, bone mineral apparent density, bone turnover markers, liraglutide, GLP-1 receptor agonists, bone metabolism, adult height
- MeSH terms
- Liraglutide, Adult, Body Composition, Body Height, Bone and Bones, Female, Humans, Male, Mutation, Organ Size, Absorptiometry, Photon, Bone Density, Case-Control Studies, Bone Remodeling, Receptor, Melanocortin, Type 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.